Biogen’s clinical-stage pipeline carries little weight, and encouraging data in lupus is unlikely to change that.
Twin setbacks for grass pollen allergy projects in development by Asit Biotech and Allergy Therapeutics expose an existential crisis.
With data showing superiority over glucocorticoids, Chemocentryx could have a new standard of care for vasculitis in avacopan.
After a delay Wave will finally see data for its Huntington's disease projects while Argenx's subcutaneous efgartigimod needs to keep the competition at bay.
Astrazeneca’s goal of bringing the second new lupus drug in over half a century to the market is a step closer, but all hangs on the FDA accepting mixed clinical data.
Kadmon awaits key graft-versus-host disease data, and Surface Oncology's change of tack comes under the spotlight.
Questions about clinical data aside, Imfinzi and tremelimumab could be filed for first-line lung cancer by the end of the year.
A week after UCB bought Ra to get hold of its complement inhibitor, Alexion takes out Achillion for much the same reason.
In liver cancer Roche hopes to succeed where Bristol failed, while Incyte tests its Jakafi follow-on in first-line graft-versus-host disease.